Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 48

1.

Macrolides, Digoxin Toxicity and the Risk of Sudden Death: A Population-Based Study.

Quinn KL, Macdonald EM, Gomes T, Mamdani MM, Huang A, Juurlink DN; Canadian Drug Safety and Effectiveness Research Network (CDSERN)..

Drug Saf. 2017 Apr 18. doi: 10.1007/s40264-017-0539-9. [Epub ahead of print]

PMID:
28421551
2.

Azithromycin Causes a Novel Proarrhythmic Syndrome.

Yang Z, Prinsen JK, Bersell KR, Shen W, Yermalitskaya L, Sidorova T, Luis PB, Hall L, Zhang W, Du L, Milne G, Tucker P, George AL Jr, Campbell CM, Pickett RA, Shaffer CM, Chopra N, Yang T, Knollmann BC, Roden DM, Murray KT.

Circ Arrhythm Electrophysiol. 2017 Apr;10(4). pii: e003560. doi: 10.1161/CIRCEP.115.003560.

PMID:
28408648
3.

Is cardiovascular risk a concern when prescribing azithromycin?

Sutton SS.

JAAPA. 2017 Jan;30(1):11-13. doi: 10.1097/01.JAA.0000511033.34198.95.

PMID:
28033168
4.

Incidence of Sustained Ventricular Tachycardia in Patients with Prolonged QTc After the Administration of Azithromycin: A Retrospective Study.

Sears SP, Getz TW, Austin CO, Palmer WC, Boyd EA, Stancampiano FF.

Drugs Real World Outcomes. 2016 Mar;3(1):99-105.

PMID:
27747808
5.
7.

Incidence of Sustained Ventricular Tachycardia in Patients with Prolonged QTc After the Administration of Azithromycin: A Retrospective Study.

Sears SP, Getz TW, Austin CO, Palmer WC, Boyd EA, Stancampiano FF.

Drugs Real World Outcomes. 2016;3:99-105. Epub 2016 Mar 14.

8.

The Role of Macrolide Antibiotics in Increasing Cardiovascular Risk.

Cheng YJ, Nie XY, Chen XM, Lin XX, Tang K, Zeng WT, Mei WY, Liu LJ, Long M, Yao FJ, Liu J, Liao XX, Du ZM, Dong YG, Ma H, Xiao HP, Wu SH.

J Am Coll Cardiol. 2015 Nov 17;66(20):2173-84. doi: 10.1016/j.jacc.2015.09.029.

9.

Azithromycin and Risk of Cardiovascular Death: A Meta-Analytic Review of Observational Studies.

Bin Abdulhak AA, Khan AR, Garbati MA, Qazi AH, Erwin P, Kisra S, Aly A, Farid T, El-Chami M, Wimmer AP.

Am J Ther. 2015 Sep-Oct;22(5):e122-9. doi: 10.1097/MJT.0000000000000138. Review.

PMID:
25748818
11.

Cardiac risks associated with antibiotics: azithromycin and levofloxacin.

Lu ZK, Yuan J, Li M, Sutton SS, Rao GA, Jacob S, Bennett CL.

Expert Opin Drug Saf. 2015 Feb;14(2):295-303. doi: 10.1517/14740338.2015.989210. Epub 2014 Dec 10. Review.

12.

Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and β-lactam/β-lactamase inhibitors: a Taiwanese nationwide study.

Chou HW, Wang JL, Chang CH, Lai CL, Lai MS, Chan KA.

Clin Infect Dis. 2015 Feb 15;60(4):566-77. doi: 10.1093/cid/ciu914. Epub 2014 Nov 18.

PMID:
25409476
13.

Azithromycin and the risk of cardiovascular complications.

Maisch NM, Kochupurackal JG, Sin J.

J Pharm Pract. 2014 Oct;27(5):496-500. Review.

PMID:
25374989
14.

Azithromycin Can Prolong QT Interval and Suppress Ventricular Contraction, but Will Not Induce Torsade de Pointes.

Ohara H, Nakamura Y, Watanabe Y, Cao X, Yamazaki Y, Izumi-Nakaseko H, Ando K, Yamazaki H, Yamazaki J, Ikeda T, Sugiyama A.

Cardiovasc Toxicol. 2015 Jul;15(3):232-40. doi: 10.1007/s12012-014-9289-4.

PMID:
25367413
15.

Management and prevention of exacerbations of COPD.

Aaron SD.

BMJ. 2014 Sep 22;349:g5237. doi: 10.1136/bmj.g5237. Review.

16.

Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports.

Hancox JC, Hasnain M, Vieweg WV, Crouse EL, Baranchuk A.

Ther Adv Infect Dis. 2013 Oct;1(5):155-65. doi: 10.1177/2049936113501816.

17.

Lack of association between azithromycin and death from cardiovascular causes.

Khosropour CM, Capizzi JD, Schafer SD, Kent JB, Dombrowski JC, Golden MR.

N Engl J Med. 2014 May 15;370(20):1961-2. doi: 10.1056/NEJMc1401831. No abstract available.

18.

[Long-term macrolide treatment in adult chronic bronchial diseases: benefits and limits].

Jouneau S, Desrues B.

Presse Med. 2014 May;43(5):510-9. doi: 10.1016/j.lpm.2013.08.006. Epub 2014 Mar 14. French.

PMID:
24631048
19.

Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death.

Rao GA, Mann JR, Shoaibi A, Bennett CL, Nahhas G, Sutton SS, Jacob S, Strayer SM.

Ann Fam Med. 2014 Mar-Apr;12(2):121-7. doi: 10.1370/afm.1601.

20.

Azithromycin-induced proarrhythmia and cardiovascular death.

Howard PA.

Ann Pharmacother. 2013 Nov;47(11):1547-51. doi: 10.1177/1060028013504905. Review.

PMID:
24285766

Supplemental Content

Loading ...
Support Center